Nature May 2016 PMID 27144355

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

Panos Zanos, Ruin Moaddel, Patrick J Morris, Polymnia Georgiou, Jonathan Fischell, Greg I Elmer, Manickavasagom Alkondon, Peixiong Yuan, Heather J Pribut, Nagendra S Singh, Katina S S Dossou, Yuhong Fang, Xi-Ping Huang, Cheryl L Mayo, Irving W Wainer

Full text PDF Download social card

Mentions

Peak: 1 in May 2021

across 6 sources since May 2021

Extended reach

10,420

potential audience

Total likes

247

Video views

9,635

Mentions per month

May 2021 – Jul 2023

Where it's discussed

News53 articles
Blogs23 articles
Facebook10 posts
Reddit3 posts
YouTube2 videos
X / Twitter1 posts

AI synopsis

What people are saying

The discussions generally express agreement with the article's findings, emphasizing the potential for safer, faster antidepressants through phrases like 'game-changing' and 'promising new approach.' Participants also show high interest, frequently referencing the mechanisms involving AMPA receptors and the bypassing of NMDAR inhibition, which illustrates their engagement with the scientific content. While some posts speculate on future applications, the overall tone indicates recognition of the study's significant impact on depression treatment research.

AgreementModerate agreement

Most discussions acknowledge the significance of the findings, with some expressing strong support for the novel mechanisms proposed.

InterestHigh interest

Participants demonstrate high curiosity and enthusiasm, often highlighting the potential for new treatments for depression.

EngagementModerate engagement

Several posts delve into details about the mechanisms and implications, indicating active engagement.

ImpactModerate impact

The discussions suggest a moderate to high perception of the research's importance, especially regarding therapeutic advancements.

Abstract in brief

The study explores how ketamine's antidepressant effects are largely due to its metabolite, hydroxynorketamine (HNK), specifically the 2R6R-HNK enantiomer, which works independently of NMDAR inhibition and instead activates AMPA receptors.
Researchers found that ketamine's ability to treat depression depends on its conversion to HNK, and that this metabolite produces rapid antidepressant effects in mice without ketamine's usual side effects.
These findings suggest a new mechanism for antidepressant action that could lead to the development of faster, safer treatments for depression, bypassing the need for NMDAR inhibition.]

Read the full abstract

All mentions

Psilocybin's Therapeutic Effects and 5HT2A Receptor Controversy

It is unclear how psilocybin exerts its therapeutic effects, as studies usually link it to 5HT2A receptors. However, recent research suggests otherwise. This video discusses a rodent study's findings on psilocybin's…

Neuropharmacist · May 1, 2021 8,105 views

Hydroxynorketamines: New Mechanisms for Rapid Antidepressant Effects

Ketamine's rapid antidepressant effects are traditionally linked to NMDAR blockade, but recent research highlights metabolites like hydroxynorketamine that have antidepressant-like effects via AMPA receptor activation…

Neuropharmacist · Jun 5, 2021 1,530 views

FMCH Journal

@FMCHJournal · X

NMDAR inhibition-independent antidepressant actions of ketamine metabolites Read More On https://t.co/CrjF9QuYL5 https://t.co/HUoEkGvlvO

Jul 27, 2023 · 786 followers View post →